What’s Trending?

FDA
The U.S. Food and Drug Administration today granted final approval of the first generic naloxone hydrochloride nasal spray, commonly known as Narcan, a life-saving medication that can stop or reverse the effects of an opioid overdose. The agency is also planning new steps to prioritize the review of additional generic [...]
Fri, Apr 19, 2019
Source WorldPharmaNews
Lawyers representing opioid makers filed an emergency motion Wednesday night asking the judge in a multistate case to throw out reports from expert witnesses that estimate the companies would need to pay $480 billion in damages. But the judge was having none of that. [...]
Fri, Apr 19, 2019
Source FiercePharma
A group of Indian generics makers is starting to take the lead in U.S. generics prescriptions; Chi-Med has filed to list on the Hong Kong Stock Exchange; an explosion at a Qilu Pharma subsidiary killed 10 workers and injured 12. [...]
Fri, Apr 19, 2019
Source FiercePharma
What does it take to steer one of pharma's biggest whales? As Johnson & Johnson CEO Alex Gorsky told Fortune magazine, six years in the U.S. Army made all the difference. [...]
Thu, Apr 18, 2019
Source FiercePharma
What used to be a 12 million prescription advantage the “old guard” generics firms held has been overturned, and the “next six” firms—including a slew of Indian drugmakers—now boast a lead of about 2 million as of the end of March. [...]
Thu, Apr 18, 2019
Source FiercePharma
Until now, scientists have had only a limited number of tools for working out the cause of an individual's tumour. [...]
Thu, Apr 18, 2019
Source PharmaTimes
For adults who have failed to respond to, or are unsuitable for, other systemic therapies. [...]
Thu, Apr 18, 2019
Source PharmaTimes
The legal right to choice has been in place for over a decade, but just 48% of the public are currently aware of it. [...]
Thu, Apr 18, 2019
Source PharmaTimes
PureTech Health will receive up to $26 million under the transaction. [...]
Thu, Apr 18, 2019
Source PharmaTimes
Roche
In the first three months of 2019, Group sales rose 8% to CHF 14.8 billion. Sales in the Pharmaceuticals Division increased 10% to CHF 11.9 billion. Key growth drivers were the multiple sclerosis medicine Ocrevus and cancer medicines Perjeta and Tecentriq as well as the new haemophilia medicine Hemlibra. [...]
Thu, Apr 18, 2019
Source WorldPharmaNews
Cannabidiol (CBD), a non-psychoactive compound in cannabis, is being touted as beneficial for many health conditions, ranging from anxiety to epilepsy. Although much more research is needed to verify these claims, scientists have now shown that CBD could have a different use as a "Trojan horse": helping slip medications across [...]
Wed, Apr 17, 2019
Source WorldPharmaNews
Sanofi
On World Hemophilia Day April 17th, the global bleeding disorders community unites to raise awareness and understanding of hemophilia and areas of unmet needs for patients. Hemophilia is a rare, genetic bleeding disorder in which the ability of a person's blood to clot is impaired, which can lead to bleeding [...]
Wed, Apr 17, 2019
Source WorldPharmaNews
Sponsors submitting pediatric study plans should consider whether a product affects adults and children similarly when choosing an approach, the FDA says. [...]
Fri, Jan 16, 2015
Source FDANews